Literature DB >> 30368979

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Jacob W Vogel1,2, Niklas Mattsson3,4,5, Yasser Iturria-Medina1, Olof T Strandberg3, Michael Schöll3,6, Christian Dansereau7,8, Sylvia Villeneuve1,9, Wiesje M van der Flier2,10, Philip Scheltens2, Pierre Bellec7,8, Alan C Evans1, Oskar Hansson3,4, Rik Ossenkoppele2,3.   

Abstract

Previous positron emission tomography (PET) studies have quantified filamentous tau pathology using regions-of-interest (ROIs) based on observations of the topographical distribution of neurofibrillary tangles in post-mortem tissue. However, such approaches may not take full advantage of information contained in neuroimaging data. The present study employs an unsupervised data-driven method to identify spatial patterns of tau-PET distribution, and to compare these patterns to previously published "pathology-driven" ROIs. Tau-PET patterns were identified from a discovery sample comprised of 123 normal controls and patients with mild cognitive impairment or Alzheimer's disease (AD) dementia from the Swedish BioFINDER cohort, who underwent [18 F]AV1451 PET scanning. Associations with cognition were tested in a separate sample of 90 individuals from ADNI. BioFINDER [18 F]AV1451 images were entered into a robust voxelwise stable clustering algorithm, which resulted in five clusters. Mean [18 F]AV1451 uptake in the data-driven clusters, and in 35 previously published pathology-driven ROIs, was extracted from ADNI [18 F]AV1451 scans. We performed linear models comparing [18 F]AV1451 signal across all 40 ROIs to tests of global cognition and episodic memory, adjusting for age, sex, and education. Two data-driven ROIs consistently demonstrated the strongest or near-strongest effect sizes across all cognitive tests. Inputting all regions plus demographics into a feature selection routine resulted in selection of two ROIs (one data-driven, one pathology-driven) and education, which together explained 28% of the variance of a global cognitive composite score. Our findings suggest that [18 F]AV1451-PET data naturally clusters into spatial patterns that are biologically meaningful and that may offer advantages as clinical tools.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  AV1451; Alzheimer's disease; cognition; data-driven; tau-PET

Mesh:

Substances:

Year:  2018        PMID: 30368979      PMCID: PMC6865737          DOI: 10.1002/hbm.24401

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  58 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.

Authors:  Kenichi Ota; Naoya Oishi; Kengo Ito; Hidenao Fukuyama
Journal:  J Neurosci Methods       Date:  2015-08-28       Impact factor: 2.390

3.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Authors:  Adam J Schwarz; Peng Yu; Bradley B Miller; Sergey Shcherbinin; James Dickson; Michael Navitsky; Abhinay D Joshi; Michael D Devous; Mark S Mintun
Journal:  Brain       Date:  2016-03-02       Impact factor: 13.501

4.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo
Journal:  Ann Neurol       Date:  2016-07-08       Impact factor: 10.422

5.  Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.

Authors:  Ineke A van Rossum; Pieter Jelle Visser; Dirk L Knol; Wiesje M van der Flier; Charlotte E Teunissen; Frederik Barkhof; Marinus A Blankenstein; Philip Scheltens
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease.

Authors:  Hanna Cho; Jae Yong Choi; Seung Ha Lee; Jae Hoon Lee; Young-Chul Choi; Young Hoon Ryu; Myoung Sik Lee; Chul Hyoung Lyoo
Journal:  Neurobiol Aging       Date:  2017-02-09       Impact factor: 4.673

7.  Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease.

Authors:  Ryuichi Harada; Aiko Ishiki; Hideaki Kai; Naomi Sato; Katsutoshi Furukawa; Shozo Furumoto; Tetsuro Tago; Naoki Tomita; Shoichi Watanuki; Kotaro Hiraoka; Yoichi Ishikawa; Yoshihito Funaki; Tadaho Nakamura; Takeo Yoshikawa; Ren Iwata; Manabu Tashiro; Hironobu Sasano; Tetsuyuki Kitamoto; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo; Nobuyuki Okamura
Journal:  J Nucl Med       Date:  2017-09-01       Impact factor: 10.057

8.  Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.

Authors:  Anne Maass; Samuel N Lockhart; Theresa M Harrison; Rachel K Bell; Taylor Mellinger; Kaitlin Swinnerton; Suzanne L Baker; Gil D Rabinovici; William J Jagust
Journal:  J Neurosci       Date:  2017-11-30       Impact factor: 6.167

9.  [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Chester A Mathis; William E Klunk
Journal:  Ann Neurol       Date:  2016-07-07       Impact factor: 10.422

10.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.

Authors:  Kok Pin Ng; Tharick A Pascoal; Sulantha Mathotaarachchi; Joseph Therriault; Min Su Kang; Monica Shin; Marie-Christine Guiot; Qi Guo; Ryuichi Harada; Robert A Comley; Gassan Massarweh; Jean-Paul Soucy; Nobuyuki Okamura; Serge Gauthier; Pedro Rosa-Neto
Journal:  Alzheimers Res Ther       Date:  2017-03-31       Impact factor: 6.982

View more
  15 in total

1.  Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.

Authors:  Irene Sintini; Jonathan Graff-Radford; Matthew L Senjem; Christopher G Schwarz; Mary M Machulda; Peter R Martin; David T Jones; Bradley F Boeve; David S Knopman; Kejal Kantarci; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

Review 2.  Neuroimaging of traumatic brain injury in military personnel: An overview.

Authors:  Avnish Bhattrai; Andrei Irimia; John Darrell Van Horn
Journal:  J Clin Neurosci       Date:  2019-07-19       Impact factor: 1.961

Review 3.  Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease.

Authors:  Rachel F Buckley
Journal:  Neurotherapeutics       Date:  2021-03-29       Impact factor: 7.620

4.  Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Authors:  Jacob W Vogel; Niklas Mattsson; Yasser Iturria-Medina; Olof T Strandberg; Michael Schöll; Christian Dansereau; Sylvia Villeneuve; Wiesje M van der Flier; Philip Scheltens; Pierre Bellec; Alan C Evans; Oskar Hansson; Rik Ossenkoppele
Journal:  Hum Brain Mapp       Date:  2018-10-19       Impact factor: 5.038

5.  Four distinct trajectories of tau deposition identified in Alzheimer's disease.

Authors:  Jacob W Vogel; Alexandra L Young; Neil P Oxtoby; Ruben Smith; Rik Ossenkoppele; Olof T Strandberg; Renaud La Joie; Leon M Aksman; Michel J Grothe; Yasser Iturria-Medina; Michael J Pontecorvo; Michael D Devous; Gil D Rabinovici; Daniel C Alexander; Chul Hyoung Lyoo; Alan C Evans; Oskar Hansson
Journal:  Nat Med       Date:  2021-04-29       Impact factor: 53.440

6.  Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.

Authors:  Gemma Salvadó; Michel J Grothe; Colin Groot; Alexis Moscoso; Michael Schöll; Juan Domingo Gispert; Rik Ossenkoppele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-01       Impact factor: 9.236

7.  Indication of retrograde tau spreading along Braak stages and functional connectivity pathways.

Authors:  Joseph Seemiller; Gérard N Bischof; Merle C Hoenig; Masoud Tahmasian; Thilo van Eimeren; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-18       Impact factor: 10.057

8.  Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease.

Authors:  Alan C Evans; Oskar Hansson; Jacob W Vogel; Yasser Iturria-Medina; Olof T Strandberg; Ruben Smith; Elizabeth Levitis
Journal:  Nat Commun       Date:  2020-05-26       Impact factor: 14.919

9.  Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain.

Authors:  Rik Ossenkoppele; Leonardo Iaccarino; Daniel R Schonhaut; Jesse A Brown; Renaud La Joie; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Joel H Kramer; Maria-Luisa Gorno-Tempini; Bruce L Miller; Howard J Rosen; William W Seeley; William J Jagust; Gil D Rabinovici
Journal:  Neuroimage Clin       Date:  2019-05-02       Impact factor: 4.881

10.  A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.

Authors:  Antoine Leuzy; Tharick A Pascoal; Olof Strandberg; Philip Insel; Ruben Smith; Niklas Mattsson-Carlgren; Andréa L Benedet; Hannah Cho; Chul H Lyoo; Renaud La Joie; Gil D Rabinovici; Rik Ossenkoppele; Pedro Rosa-Neto; Oskar Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.